Last reviewed · How we verify
HA 0.3%
HA 0.3% is a hyaluronic acid-based topical or injectable formulation that provides hydration, lubrication, and tissue support through its viscoelastic properties.
HA 0.3% is a hyaluronic acid-based topical or injectable formulation that provides hydration, lubrication, and tissue support through its viscoelastic properties. Used for Dry eye syndrome or ocular surface disease (if ophthalmic formulation), Wound healing or skin hydration (if dermatologic formulation).
At a glance
| Generic name | HA 0.3% |
|---|---|
| Sponsor | Huons Co., Ltd. |
| Drug class | Hyaluronic acid derivative |
| Target | Hyaluronic acid receptors (CD44, RHAMM) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology or Dermatology |
| Phase | Phase 3 |
Mechanism of action
Hyaluronic acid (HA) is a naturally occurring polysaccharide that binds water and maintains tissue hydration and elasticity. When formulated at 0.3% concentration, it is used to restore moisture, reduce friction, and support tissue integrity in affected areas. The mechanism relies on HA's hygroscopic properties and its role in maintaining the extracellular matrix.
Approved indications
- Dry eye syndrome or ocular surface disease (if ophthalmic formulation)
- Wound healing or skin hydration (if dermatologic formulation)
Common side effects
- Local irritation or discomfort
- Transient blurred vision (if ophthalmic)
- Allergic reaction
Key clinical trials
- To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome (PHASE3)
- Clinical Investigation for Evaluating the Safety and Efficacy of JTM102 to Mid Face Volume Deficiency (NA)
- Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit (NA)
- A Comparative Study of Selective Dorsal Neurectomy, Pulsed Radiofrequency Neuromodulation, and Intragranular Hyaluronic Acid Injection for Premature Ejaculation (NA)
- Saypha® VOLUME Lidocaine for Midface Augmentation (PHASE3)
- Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis (PHASE4)
- Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang
- Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HA 0.3% CI brief — competitive landscape report
- HA 0.3% updates RSS · CI watch RSS
- Huons Co., Ltd. portfolio CI